Lyell Immunopharma, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Lyell Immunopharma, Inc. (LYEL) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $1.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $4.61M.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.57M.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $4.90M.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $572.00K, a 81.51% decline year-over-year.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$7.64M.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.25M.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$719.00K.
- Lyell Immunopharma, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$463.00K, a 110.19% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.04M 10-Q · filed 2026-08-06 | $5.95M derived: sum of 3 quarters · filed 2026-08-06 | $6.52M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$3.57M 10-Q · filed 2026-05-06 | $1.34M derived: sum of 2 quarters · filed 2026-05-06 | $1.91M derived: sum of 3 quarters · filed 2026-05-06 | -$1.42M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $4.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.48M derived: sum of 2 quarters · filed 2026-03-12 | $2.15M derived: sum of 3 quarters · filed 2026-08-06 | -$7.64M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $572.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.76M derived: sum of 2 quarters · filed 2026-08-06 | -$12.55M 10-Q · filed 2025-11-12 | -$13.80M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$13.12M 10-Q · filed 2026-08-06 | -$14.37M derived: sum of 3 quarters · filed 2026-08-06 | -$11.28M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$9.79M 10-Q · filed 2026-05-06 | -$11.04M derived: sum of 2 quarters · filed 2026-05-06 | -$7.95M derived: sum of 3 quarters · filed 2026-05-06 | -$7.43M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.84M derived: sum of 2 quarters · filed 2026-03-12 | $2.36M derived: sum of 3 quarters · filed 2026-03-12 | -$1.25M 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.61M derived: sum of 2 quarters · filed 2025-11-12 | $4.00K 10-Q · filed 2025-11-12 | -$1.74M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-06-30 | $516.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$3.09M 10-Q · filed 2025-08-12 | -$4.83M derived: sum of 3 quarters · filed 2026-03-12 | -$217.00K derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2024-03-31 | -$3.61M 10-Q · filed 2025-05-13 | -$5.34M derived: sum of 2 quarters · filed 2026-03-12 | -$733.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.53M derived: sum of 4 quarters · filed 2026-03-12 | ||
| 2023-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.87M derived: sum of 2 quarters · filed 2026-03-12 | $5.14M derived: sum of 3 quarters · filed 2026-03-12 | -$719.00K 10-K · filed 2026-03-12 | ||
| 2023-09-30 | $4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.88M derived: sum of 2 quarters · filed 2024-11-07 | $1.02M 10-Q · filed 2024-11-07 | $6.39M derived: sum of 4 quarters · filed 2025-03-11 | ||
| 2023-06-30 | $2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$3.59M 10-Q · filed 2024-08-07 | $1.78M derived: sum of 3 quarters · filed 2025-03-11 | $3.10M derived: sum of 4 quarters · filed 2025-03-11 | ||
| 2023-03-31 | -$5.86M 10-Q · filed 2024-05-06 | -$487.00K derived: sum of 2 quarters · filed 2025-03-11 | $836.00K derived: sum of 3 quarters · filed 2025-03-11 | $70.00K derived: sum of 4 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $6.70M derived: sum of 2 quarters · filed 2025-03-11 | $5.93M derived: sum of 3 quarters · filed 2025-03-11 | -$463.00K 10-K · filed 2025-03-11 | ||
| 2022-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $557.00K derived: sum of 2 quarters · filed 2023-11-07 | -$5.84M 10-Q · filed 2023-11-07 | -$1.62M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | -$766.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$7.16M 10-Q · filed 2023-08-08 | -$2.94M derived: sum of 3 quarters · filed 2024-02-28 | -$1.01M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | -$6.39M 10-Q · filed 2023-05-04 | -$2.18M derived: sum of 2 quarters · filed 2024-02-28 | -$240.00K derived: sum of 3 quarters · filed 2024-02-28 | $2.84M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $6.15M derived: sum of 2 quarters · filed 2024-02-28 | $9.24M derived: sum of 3 quarters · filed 2024-02-28 | $4.54M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $5.02M derived: sum of 2 quarters · filed 2022-11-08 | $325.00K 10-Q · filed 2022-11-08 | $10.79M 10-Q · filed 2021-11-12 | $2.24M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.61M 10-Q · filed 2022-08-04 | $3.68M 10-Q · filed 2021-08-12 | $300.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.15M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | -$4.70M 10-Q · filed 2022-05-10 | -$2.78M derived: sum of 2 quarters · filed 2023-02-28 | -$1.94M derived: sum of 3 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.76M derived: sum of 2 quarters · filed 2023-02-28 | $6.12M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $848.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $4.21M 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $3.36M 10-Q · filed 2021-08-12 | |||||
| 2019-12-31 | $9.76M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |